Pharma Manufacturing

The global pharma market is set to be worth $1.7 trillion by 2025, and it is predicted that the US (39%) and China (12%) will represent more than 50% of business. This means that the pharmaceutical sector in Europe has a considerable amount of work to do in order to remain a powerhouse on the world stage.

European pharmaceutical sector:

€0 bn

Projected pharmaceutical sales for 2027

0 %

of pharma sales on the world market stem from Europe

0 k

People employed in the sector

Massive sector changes

The European pharmaceutical manufacturing sector is under considerable pressure from:

Globalisation

Pharmaceutical supply chains have become increasingly complex due to the shift of manufacturing and critical operations to Asia. Vulnerabilities stem from complex regulatory landscape, difficulties for enforcement of quality standards at foreign facilities and single-source supply chains

Around 60 percent of pharmaceutical manufacturing is outsourced

Supply chain complexity

Manufacturing delays and capacity issues that continue to impact the pharmaceutical supply chain have led to medicine shortages around the globe; an issue that has been exacerbated further by geopolitical events, the energy crisis and rising inflation

Costs have risen from 50-160% in some cases

Evolving regulations

The European medicines regulatory system is complex, unique and constantly evolving. Earlier this year the European Commission proposed a new directive and regulation to revise and replace current pharmaceutical legislation. The proposed reform of the EU's pharmaceutical sector will impact all stages in the pharmaceutical product life cycle designed to modernise the sector with a patient-centred approach that fully supports an innovative and competitive industry.

It is based on a network of around 50 regulatory authorities from the 30 EEA countries, the European Commission and EMA

Security

One of the most significant regulatory challenges in the pharmaceutical industry is how data is stored and managed. Cyber threats to the pharma industry make them prone to identity theft and evolving attack vectors. As organisations focus more on digitisation, more of their valuable data gets stored online, making them a bigger target to cyber criminals.

The average total cost of a data breach is significantly higher for the healthcare and pharmaceutical industry compared to less regulated industries such as hospitality, media, and research

.bg-image.gbi-827666890-66zC3Z9BAp9BHVsZGdHc8Q:before { opacity: 1; background-image: url('/static/cd5270a61e50cfa0cb86398c09082dda/273c4/services_background.png'); }

Accruent - Providing Pharmaceutical Manufacturers with Capabilities to Compete

Helping nine out of 10 of the world’s biggest pharmaceutical companies achieve compliance

Pharmaceutical manufacturers must adhere to industry compliance standards to introduce products to market faster and in high volumes. This requires document management systems to serve as a comprehensive solution to control, manage, and streamline documentation and information related to the manufacturing process, ultimately establishing a ‘single source of truth’. Meridian helps 9 of 10 world’s biggest pharmaceutical companies:

Maintain compliance and validation
Streamline document management
Ensure safety and compliance
Maximise company-wide collaboration
Achieve a single source of asset information

Find out more

Capitalise on the IoT that is transforming pharmaceutical manufacturing

Digitisation of processes and data across the value chain along with the emergence of the Internet of Things (IoT) is transforming the pharmaceutical sector helping to; reduce time-to-market for drugs, use real-time data feeds to proactively detect errors across the value chain, improve regulatory compliance, among other things. Our IoT Remote Monitoring Systems can help pharmaceutical companies:

Predict and prevent asset failures 3-5 days before they happen
Improve first-time fix rates
Maximise operational efficiency
Reduce equipment downtime and impacts

More information here

Improve energy efficiency to reduce operating costs and meet sustainability goals

The pharmaceutical manufacturing sector needs to maintain critical environments for production in terms of temperature, humidity, room pressurisation, cleanliness, and containment. It is why the sector is spending more than USD1 billion on energy consumption every year and generating 55% more emissions than the automotive industry. This is where Observe for Energy Management can help by providing monitoring and targeting capabilities to:

Identify savings opportunities
Lower costs
Reach energy consumption targets
Meet sustainability goals

Find out more

Prioritise mission-critical machinery to deliver maximum ROI

Pharma companies are prioritising maintenance tasks based on criticality and impact on operations, emphasising the importance of preventive measures to reduce failure. Maintenance Connection, which can be deployed in a Software-as-a-Service (SaaS) or on-premise model can help maintenance teams: